Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) announced a positive CHMP opinion recommending EU approval of Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis (AD) inadequately controlled by topical corticosteroids and calcineurin inhibitors.
Phase 3 TRuE‑AD4 showed significant EASI75 and IGA-TS responses, sustained control to Week 24, and a favorable 24‑week safety profile. The European Commission will now review the opinion, potentially granting a second EU indication after non-segmental vitiligo.
Incyte (NASDAQ:INCY) announced that Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) plus lenalidomide to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
Approval is supported by Phase II L-MIND and Phase Ib/II J-MIND trial results showing response rates up to 71.4%. According to Incyte, Minjuvi plus lenalidomide delivered clinically meaningful responses with manageable side effects, mainly neutropenia and thrombocytopenia. This is Minjuvi’s second approval in Japan.
Mirum Pharmaceuticals (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) reported pivotal Phase 2 PROGRESS data for zilurgisertib in fibrodysplasia ossificans progressiva (FOP). In 63 patients ≥12 years, zilurgisertib showed large reductions in new and existing heterotopic ossification (HO) lesion volume and maintained low flare activity through Week 48. Zilurgisertib was generally well tolerated, with mainly mild to moderate adverse events. The FDA accepted the NDA with Priority Review for FOP patients ≥12 years, with a PDUFA target action date of September 26, 2026.
Incyte (Nasdaq:INCY) reported updated Phase 1 data for INCA033989, a first-in-class mutant calreticulin antibody, in myelofibrosis (MF) and essential thrombocythemia (ET).
INCA033989 showed rapid, durable clinical and molecular responses with high spleen, symptom, anemia and hematologic response rates and generally manageable safety, and has FDA Breakthrough Therapy designation in ET and a Phase 3 ET trial starting mid-2026.
Incyte (Nasdaq: INCY) reported pivotal Phase 3 frontMIND results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide added to R-CHOP in previously untreated high-risk DLBCL and HGBL.
Tafa-Len-R-CHOP cut risk of progression or death by 25%, improved PFS and EFS, raised MRD-negativity rates, and showed manageable but higher Grade ≥3 and fatal adverse events, supporting global regulatory applications.
Incyte (Nasdaq: INCY) agreed to acquire Vega Therapeutics, a wholly owned Star Therapeutics subsidiary, for $1.25 billion upfront, plus up to $750 million in sales milestones, for potential consideration of $2.0 billion.
The deal adds VGA039, a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease, with multiple FDA designations. Closing is expected in Q3 2026, triggering an estimated $1.25 billion R&D charge to Incyte’s 2026 GAAP and non-GAAP results.
Incyte (Nasdaq: INCY) and Mirum Pharmaceuticals will present pivotal Phase 2 PROGRESS study results for investigational ALK2 inhibitor zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026 in Chicago, June 13-16, 2026.
The Cohort 1, placebo-controlled data supported the New Drug Application, which has an FDA Priority Review PDUFA date of September 26, 2026.
Incyte (Nasdaq: INCY) reported pivotal Phase 3 frontMIND results in previously untreated, high-risk DLBCL/HGBL. Adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP reduced risk of progression or death by 25% (HR 0.75, P=0.0194) versus R-CHOP alone.
Two-year PFS was 71.1% vs 62.9%; three-year PFS 67.3% vs 60.7%. Event-free survival improved (HR 0.79, P=0.0260). Interim overall survival showed a favorable trend (HR 0.85). Safety was manageable, though Grade ≥3 and fatal adverse events were higher with Tafa-Len-R-CHOP. The data support planned global regulatory submissions.
Incyte (Nasdaq: INCY) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT.
The presentation will be webcast live via Incyte's investor website and available for 30-day replay.
Incyte (Nasdaq: INCY) and Genesis Molecular AI expanded their collaboration to use Genesis’ GEMS molecular AI platform and Incyte’s proprietary experimental data to discover novel small-molecule drugs. Genesis receives $120M upfront ($80M cash, $40M equity), recurring research funding, and is eligible for up to $232M per program in milestones, over $1B across five initial targets, plus royalties, while Incyte gains exclusive rights to develop and commercialize collaboration products and options to nominate additional targets.